PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

Summary

An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.

Timeline

Start

2025-09-01

Primary completion

2029-12-01

Completion

2029-12-01

Drugs

Indications